Larvol Delta - BA3021002-A-Phase-2-Open-Label-Study-of-BA3021-in-Patients-With-Recurrent-or-Metastatic-Squamous-Cell-Carcinoma-of-the-Head-and-Neck

ozuriftamab vedotin (BA3021) - BioAtla

evalstotug (BA3071) - BioAtla

Erbitux (cetuximab) - Eli Lilly

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT05271604

Sep 27, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next